Market Overview

Alnylam Makes History With Approval Of RNA Therapy

Share:
Alnylam Makes History With Approval Of RNA Therapy
Related ALNY
5 Biotech Companies To Keep On Your M&A Watchlist For 2019
Benzinga's Top Upgrades, Downgrades For November 29, 2018
Alnylam settles litigation with Silence Therapeutics (Seeking Alpha)

Biopharmaceutical company Alnylam Pharmaceuticals (NASDAQ: ALNY) made history this week by kickstarting the future of gene therapy and disease research.

What Happened

On Friday, the U.S. Food and Drug Administration approved Onpattro, the first RNA-based therapy used to treat a rare disease, polyneuropathy. The treatment is designed to silence messenger RNA, blocking the production of certain harmful proteins.

Why It’s Important

The landmark approval is for the treatment of a rare form of polyneuropathy that is caused by hATTR that affects 50,000 people worldwide.

The disease is debilitating and often fatal, as it affects peripheral nerves, the heart and other organs, according to the FDA. 

“This approval is part of a broader wave of advances that allow us to treat disease by actually targeting the root cause, enabling us to arrest or reverse a condition, rather than only being able to slow its progression or treat its symptoms,” FDA Commissioner Scott Gottlieb said in the press release. 

“In this case, the effects of the disease cause a degeneration of the nerves, which can manifest in pain, weakness and loss of mobility.”

What’s Next

New technologies such as those developed by Alnylam have the ability to transform medicine, giving researchers more exposure to treat and cure diseases, Gottlieb said. 

“We’re committed to advancing scientific principles that enable the efficient development and review of safe, effective and groundbreaking treatments that have the potential to change patients’ lives."

The new drug should hit the market in 48 hours, according to Alnylam CEO John Maraganore.

Bloomberg reported that Alnylam has listed the annual average list price for Onpattro at $450,000, but the price could be reduced to $350,000 with discounts. 

Related Links:

With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip

Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'

Posted-In: Onpattro polyneuropathy RNABiotech News FDA General Best of Benzinga

 

Related Articles (ALNY)

View Comments and Join the Discussion!

FDA Approves New Form Of Self-Administered Female Birth Control

Should Investors Buy The Dip In Dropbox? 4 Analysts Weigh In